Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono)
about
Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studiesGlucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes: Past, present, and futurePancreatic regulation of glucose homeostasisLixisenatide in type 2 diabetes: latest evidence and clinical usefulnessCombining incretin-based therapies with insulin: realizing the potential in type 2 diabetesLixisenatide as add-on therapy to basal insulinTreatment of type 2 diabetes, lifestyle, GLP1 agonists and DPP4 inhibitorsEffects of lixisenatide on elevated liver transaminases: systematic review with individual patient data meta-analysis of randomised controlled trials on patients with type 2 diabetesCardiovascular Effect of Incretin-Based Therapy in Patients with Type 2 Diabetes Mellitus: Systematic Review and Meta-AnalysisPharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus.Lixisenatide Improves Glycemic Control in Asian Type 2 Diabetic Patients Inadequately Controlled With Oral Antidiabetic Drugs: An Individual Patient Data Meta-AnalysisLixisenatide: first global approval.Lixisenatide resensitizes the insulin-secretory response to intravenous glucose challenge in people with type 2 diabetes--a study in both people with type 2 diabetes and healthy subjects.The clinical development program of lixisenatide: a once-daily glucagon-like Peptide-1 receptor agonist.Pharmacodynamics of the glucagon-like peptide-1 receptor agonist lixisenatide in Japanese and Caucasian patients with type 2 diabetes mellitus poorly controlled on sulphonylureas with/without metformin.Efficacy and safety of lixisenatide in Japanese patients with type 2 diabetes mellitus inadequately controlled by sulfonylurea with or without metformin: Subanalysis of GetGoal-SNovel Agents for the Treatment of Type 2 Diabetes.Lixisenatide accelerates restoration of normoglycemia and improves human beta-cell function and survival in diabetic immunodeficient NOD-scid IL-2rg(null) RIP-DTR mice engrafted with human islets.Efficacy and Acceptability of Glycemic Control of Glucagon-Like Peptide-1 Receptor Agonists among Type 2 Diabetes: A Systematic Review and Network Meta-AnalysisRandomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia).Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise.Lixisenatide reduces postprandial hyperglycaemia via gastrostatic and insulinotropic effects.Glucagon-like peptide-1 protects against cardiac microvascular injury in diabetes via a cAMP/PKA/Rho-dependent mechanism.Lixisenatide: A New Member of the Glucagon-Like Peptide 1 Receptor Agonist Class of Incretin Therapies.Clinical potential of lixisenatide once daily treatment for type 2 diabetes mellitusAdding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-Duo 1).Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L)Efficacy and safety of lixisenatide once-daily morning or evening injections in type 2 diabetes inadequately controlled on metformin (GetGoal-M).Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin.Efficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled on metformin: a 24-week, randomized, open-label, active-controlled study (GetGoal-X).Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists.Clinical application of glucagon-like Peptide 1 receptor agonists for the treatment of type 2 diabetes mellitus.Effect of the glucagon-like peptide-1 receptor agonist lixisenatide on postprandial hepatic glucose metabolism in the conscious dogPathogenesis and management of postprandial hyperglycemia: role of incretin-based therapies.A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease.Predictors of outcomes in patients with type 2 diabetes in the lixisenatide GetGoal clinical trials.A comparison of currently available GLP-1 receptor agonists for the treatment of type 2 diabetes.Recent advances in incretin-based therapies.Mechanisms and clinical efficacy of lixisenatide for the management of type 2 diabetes.Lixisenatide: a review of its use in patients with type 2 diabetes mellitus.
P2860
Q24568148-1A40A87B-1F9F-4F07-809A-C29C8030CAE5Q26752699-1D02B02D-A11E-4DDB-B1FE-5B50605EF74FQ26766485-1CEB799E-76D4-4DFE-B5F4-CF5A475AA63BQ26771823-02F71218-8BE4-4BD4-8581-E309C57E116DQ27004723-6E14523B-A4D1-460A-8760-9A8E86F42DEEQ27007547-551AA16C-F577-46AE-9E57-CB87C55DDFE4Q27021870-406A36BA-B291-4693-A13E-5B27DA0213FDQ27025423-23539CCE-5290-46B4-9FBA-5BB99923A09AQ28071764-1E164828-E10E-4496-B0C2-A758E4F38C2BQ30249371-872AF242-AABF-48B7-A827-EE35CB738401Q31140045-7CABA302-F929-4F39-B36A-88F40FB736C7Q34337281-3CEFD508-1649-43A9-86EF-8041E3A20562Q34543003-43B60D43-CD65-4729-8410-B976926ED567Q34726309-02C0E042-A7FD-4571-B739-D035E67C7E47Q35035176-33990494-13BC-435F-BD0F-5ED480FA99BBQ35192193-9ACDA7A2-8F5B-4F3A-9F5F-CCA2C93309ADQ35910421-1F93A029-C6F8-4DB1-A728-A452906CAF76Q35994230-07F2F3E3-BCD6-4E43-84F9-8FA6B0A18896Q36011993-C27E841F-CD9D-45C4-8180-8367548FCDF8Q36303786-2FF2FDD1-6264-44E5-A40E-F535FE35BCDDQ36441684-E1BA35CF-3BB3-4F14-A7CF-8D927E231DDCQ36554216-B9E3A530-997E-4A3C-9832-7665B7B8A6B0Q36796024-5796B6B9-A12D-426D-96BE-F8AEFC8DEEE9Q36803151-37474DE4-440F-4747-9E66-0B940DC755CFQ36972371-078F46E0-A5D6-44C4-A78B-40EC4A947331Q37106467-C462A1D6-939F-436A-AF5C-E1979B87358AQ37106537-BF80F93B-3B64-4D51-92AA-709701826286Q37106572-AB10273B-EE66-44FB-9BE9-C14A37E6A6D2Q37119965-678C3A2F-9FB6-41A5-AF79-34899D46C2DCQ37193446-07A6C00E-F045-4D08-8A99-90715CAA3A04Q37340223-836C8714-A3FF-45CF-9892-B35D42672239Q37410215-F1190EEE-9EDD-441E-A6B8-C1A5EC50D3BEQ37439806-21973030-DD5F-4183-AAA3-15398080FBEAQ37446672-D242C841-780B-42A5-8A76-E4243CEEDDC7Q37568754-ECE7ED7A-8425-4A4A-9230-630E882B91AEQ37633547-B3803DAB-9D99-4701-BAE9-376E4DE057CEQ38020941-0653F5F7-89D9-45EB-8871-8CF21E30D229Q38026956-728E4F84-ABBE-4A98-A127-010762BA3A70Q38083047-5D355879-F809-4F5F-BAB2-BF0D533DE5E5Q38126893-28593BA5-59C0-40BB-BEBA-C676D64BB695
P2860
Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono)
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Efficacy and safety of the onc ...... type 2 diabetes (GetGoal-Mono)
@ast
Efficacy and safety of the onc ...... type 2 diabetes (GetGoal-Mono)
@en
type
label
Efficacy and safety of the onc ...... type 2 diabetes (GetGoal-Mono)
@ast
Efficacy and safety of the onc ...... type 2 diabetes (GetGoal-Mono)
@en
prefLabel
Efficacy and safety of the onc ...... type 2 diabetes (GetGoal-Mono)
@ast
Efficacy and safety of the onc ...... type 2 diabetes (GetGoal-Mono)
@en
P2093
P2860
P356
P1433
P1476
Efficacy and safety of the onc ...... type 2 diabetes (GetGoal-Mono)
@en
P2093
Denis Raccah
EFC6018 GetGoal-Mono Study Investigators
Gabor Boka
John E Gerich
Patrick Miossec
Ricardo Alvarado-Ruiz
Vivian A Fonseca
P2860
P304
P356
10.2337/DC11-1935
P407
P577
2012-03-19T00:00:00Z